|Bid||0.00 x 12000|
|Ask||0.00 x 12000|
|Day's range||15.85 - 15.90|
|52-week range||15.31 - 49.99|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Yahoo Finance's Julie Hyman discusses the reversal in Bluebird Bio shares after the FDA approved its second gene therapy.
Stock futures are lower as investors await this week's Federal Reserve monetary policy meeting.
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss how Bluebird stock is trading after the FDA approved its gene therapy treatment.
If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...